SM-102: Ionizable Lipid for Optimized mRNA Vaccine Delivery

Executive Summary: SM-102, with the chemical name heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate, is a synthetic ionizable lipid designed for lipid nanoparticle (LNP)–mediated mRNA delivery (APExBIO). It is a key excipient in mRNA vaccine formulation, supporting cellular uptake and endosomal escape of mRNA molecules (Wang et al., DOI). SM-102 is highly soluble in ethanol (≥175.8 mg/mL) but insoluble in water and DMSO. Purity is verified at ≥98.0% by MS and NMR. Machine learning and experimental studies benchmark its delivery efficiency and physicochemical parameters (Wang et al., DOI; internal).

Biological Rationale

Messenger RNA (mRNA) vaccines require efficient delivery to the cytosol to ensure antigen expression (Wang et al., 2022). Lipid nanoparticles (LNPs) are the current gold standard for mRNA delivery, protecting mRNA from extracellular nucleases and promoting cellular uptake. The ionizable lipid component, such as SM-102, is essential for complex formation with mRNA and mediating endosomal escape. In LNPs, SM-102 provides a cationic environment at acidic pH, facilitating mRNA release into the cytosol (related article). This article extends previous overviews by compiling atomic benchmarks and detailing physicochemical parameters relevant to SM-102 as a lipid nanoparticle component.

Mechanism of Action of SM-102

SM-102 functions as an ionizable lipid, meaning its head group can become positively charged at low pH. During nanoparticle formation, SM-102 interacts electrostatically with negatively charged mRNA, resulting in encapsulation within an LNP structure. Upon cellular uptake via endocytosis, the acidic endosomal environment protonates SM-102, triggering membrane destabilization and facilitating mRNA release into the cytosol (Wang et al., 2022). This mechanism is central to LNP-mediated mRNA vaccine delivery, as it overcomes cellular barriers while minimizing cytotoxicity. SM-102’s hydrophobic tail (heptadecan-9-yl) and polar headgroup together promote stable LNP assembly and efficient mRNA encapsulation (related article—this article updates comparative data with machine learning–predicted benchmarks).

Evidence & Benchmarks

• SM-102 is used as the ionizable lipid in clinically relevant mRNA LNP platforms, including those for COVID-19 vaccines (Wang et al., 2022).
• The molecular weight of SM-102 is 710.18 Da; its chemical structure enables amphiphilicity, crucial for nanoparticle self-assembly (APExBIO).
• SM-102 is insoluble in water and DMSO, but highly soluble in ethanol at ≥175.8 mg/mL (validated at 25°C; APExBIO).
• Pilot machine learning models (LightGBM, R² > 0.87) predict SM-102’s mRNA delivery efficiency based on molecular substructure and experimental IgG titers (Wang et al., 2022).
• SM-102’s storage at –20°C or below is recommended; long-term solution storage reduces purity due to hydrolysis (APExBIO).
• Animal studies confirm SM-102 LNPs induce robust in vivo mRNA expression, but with somewhat lower efficiency than MC3-based LNPs at equivalent N/P ratios (Wang et al., 2022).
• Purity is ≥98.0% by mass spectrometry and NMR (APExBIO).

Applications, Limits & Misconceptions

SM-102 is optimized for LNP-mRNA delivery, particularly in vaccine and gene therapy research. It is not designed for direct clinical administration without formulation. SM-102’s amphiphilic profile makes it suitable for a range of nucleic acid payloads, but its performance is formulation-dependent.

• Primary application: mRNA vaccine and therapeutic LNP component (internal—this article provides a denser evidence backbone and workflow parameters).
• Benchmarking: Outperforms many older cationic lipids but may underperform MC3 for some in vivo endpoints (Wang et al., DOI).
• Solubility: Only soluble in ethanol; insoluble in aqueous and DMSO solvents (APExBIO).
• Shipping: Ships on blue ice for small molecules; dry ice for modified nucleotides.
• Stability: Degraded by hydrolysis if stored in solution at >–20°C for extended periods.

Common Pitfalls or Misconceptions

• SM-102 is not water-soluble; attempts to dissolve in aqueous buffers result in precipitation and failed LNP assembly.
• Not suitable for direct in vivo use without formulation into LNPs—unformulated SM-102 is cytotoxic.
• Purity and efficacy degrade rapidly if stored above –20°C or in solution for >1 week.
• Ionizable lipid choice alone does not determine LNP potency; helper lipid, cholesterol, PEG-lipid ratios, and N/P ratio are also critical.
• SM-102 is not a universal replacement for all ionizable lipids; comparative performance varies by payload and animal model (Wang et al., 2022).

Workflow Integration & Parameters

For optimal use, SM-102 (SKU: C1042) from APExBIO should be handled under inert atmosphere, dissolved in ethanol, and used immediately for LNP formulation (product page). Typical LNP-mRNA formulations use SM-102 with cholesterol, DSPC, and PEG-lipid at molar ratios of approximately 50:38.5:10:1.5. The recommended N/P ratio (nitrogen in lipid to phosphate in mRNA) is 6:1 for in vivo delivery, as established in mouse models (Wang et al., 2022). The product should be stored at –20°C or lower, protected from moisture and light.

For advanced troubleshooting and protocol optimization, see SM-102 Lipid Nanoparticles: Optimizing mRNA Delivery Workflows—this article provides expanded, structured evidence on molecular parameters and machine learning–based predictions for LNP performance.

Conclusion & Outlook

SM-102 remains a benchmark ionizable lipid in mRNA vaccine and therapeutics research. Its physicochemical profile, validated purity, and compatibility with LNP systems enable robust mRNA delivery. Recent advances in predictive modeling and comparative benchmarking further clarify its optimal use cases and boundaries. For detailed parameters and ordering, refer to the C1042 kit from APExBIO.